BeiGene Rebrands as BeOne Medicines, Emphasizing Global Unity Against Cancer

Name Change:
BeiGene, a global oncology company, has announced its intention to change its name to BeOne Medicines Ltd., reflecting its commitment to unite the global community against cancer45.

Global Impact:
The company has already helped more than 1.4 million patients and plans to bring more than 10 new potential medicines into the clinic this year45.

Strategic Growth:
The name change is part of a broader strategic growth plan that has enabled the company's global oncology leadership since its inception in 201045.

Clinical Portfolio:
BeOne Medicines has a strong clinical portfolio, including the PD-1 inhibitor TEVIMBRA (tislelizumab) and the BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label of any BTK inhibitor14.

Global Presence:
The company operates in over 45 countries, with a significant presence in Europe, North and South America, Australia, and Asia, and has recently opened an $800 million flagship clinical R&D and manufacturing facility in New Jersey24.

Sources:

1. https://ir.beigene.com/news/beigene-announces-positive-regulatory-updates-in-europe-and-the-u-s-after-recently-regaining-global-rights/5e4692d6-d726-4989-a659-49dc97d4d7ed/

2. https://www.swissbiotech.org/listing/biotech-report-2024-how-beigene-drives-global-cancer-treatment-access/

4. https://njbia.org/beigene-unveils-proposed-name-change-to-beone-medicines/

5. https://www.afp.com/en/news/1315/beigene-unveils-proposed-name-change-beone-medicines-reaffirming-its-mission-unite-global-community-against-cancer-202411146711681